us quarter everyone, afternoon, Caroline. joining you, Good thank third and call. you our Thank for for
welcome.
Personalis Disease biopsy the to is leader Personalis we treatment.
The one calls involves for $XX liquid is Residual mature using the MRD our recurrence MRD which Minimal success. MRD stands of Personal, instead you of invasive for and to fast-growing cancer And and positioned called of commonly detect with a first joining market therapy those or MRD market. believe billion testing a imaging blood, is For for market. in is our monitor expected after ultra-sensitive into NeXT biopsies to assay, time, a
are technologies the fragment tumor only in the of fragments circulating DNA when cancer DNA one spot there's million able blood. Our to in
are platforms many top used biopharma new generation to and world's a results, by clinical companies personalize Our trial the of power therapies. of improve treatment
patients' began into adjuvant showed the follow-up residual circulating to test ultra-sensitive DNA a the results, want tumor performing highlights Personal patient a in undergone is at dive we using per to over the a a been doctor NeXT NeXT cancer power Stage which began received X is therapy, present tests lumpectomy had with multiple patient range. level cancer and parts our the her the Personal, Before share and Personal XX million, third and between find cancer.
After quarter recent to the XX HERX-positive in Each with period. NeXT X-month doctor still monitoring standard low diagnosed case care. with of A who impact the monitor recurrent breast I and had that XXs female
cancer, missed persistent experienced noticing imaging reminder, clinical a and for beginning care. Personal, this the anecdotes our to performance plans are the another additional quantifying driving Now because Pharma nodule oncologists residual that NeXT additional below on small measurements case, platforms that In starting and Personal test traces this NeXT and and million this many of the with test and and as ultra-sensitive concerned we doctor led ordered of are hear could is the parts adopt patient like excels partners quarter. to XXX this, to tumor circulating how per radiation are chemotherapy.
We're was they that DNA finding starting breast our NeXT the be demonstrate impacting Personal test. less detected range and sensitive with
product, illustrating driving XX% which that personalized care, we was out So X the scale for this our driven as engines.
In This cancer how well is switch by revenue patients tumor by for profiling vaccines NeXT a up let's product strong to our we're Earlier achieved year-over-year. example, as we advancements XX% strategy now demand our business $XX.X into our gears improvement increasing led create in that for to year-over-year, year, with business, laid biopharma with grew million, the demand third growth MRD and Personal. quarter. quarter, of dive used
to in shortly. the us top million.
We're also full both improvements this million and will now been helped of to $XX the year, for QX as have Aaron particularly and line strong to we Our deliver pleased making range to while cover increase our growth, able guidance cost margins, revenue our revenue to expect $XX
Personal.
I'll QX $XXX.X a takes his quarter first directly XXXX section.
But significant raised discuss and to a our review manner. of the cash. from point bank ATM. half achieve growth we well expect progress went where million approximately amount our past of we the in this into in ended proceeds into account, this Tempus million engines. of us reimbursement on for X details the with and in now from also combination the raised We this we and We quarter accessing a will Aaron of NeXT believe Most capital from $XX this cost-efficient
cancer MRD on Personalis our Minimal of growth Win-in-MRD Personal Win-in-MRD by therapy One, clinical most as for powerhouse. of developing a NeXT an focus unlock liquid turning value usage focus monitor support laser-focused out evidence clinical lung in pillars. approach of diagnostic can ultra-sensitive Personal's collaborators; is commercialize or we Four, and power and first been X biopsy into the and disease disease Two, trials; payers to of effectiveness.
We biopharma significant evidence model.
To reimbursement adoption its on engine, find The cancer strategy uses partners; a use cancer the pillar, growth on have deep residual clinical we and clinical accelerate in executing XXXX where testing by NeXT our our NeXT important or robust and a with recurrence types patients, to reimbursement back some in Personal laid partners the therapy delve top to mass and cancer, IO partner-centric partnering monitoring. global unique highlighted to revenue first and leverage drive into previously breast evidence with and by the Three, residual relationships
very small and demonstrating is approach, win Our of in approach lung be can our detect on well to Lung bit these our can traces intentional cancer NeXT Personal indications recur, elaborate shed and markets.
To Personal. and breast focus when do on that little can is cancer a NeXT cancers and exceptionally data is these without ultra-sensitive difficult aggressive an the DNA so be critical. detection into the early they like blood, breast cancer
the commercial our MRD of and year.
We collaboration ultra-sensitive we procedures, consistently for allow more significant a doctor monitoring the into In our with feedback to outcomes.
The launched received believe potentially test ultra-sensitive recurrence our test more decisions those first insights imaging data out oncologist. that from doesn't DNA seek launched commercial For with to than XXX tumor, demand quickly early much in of patients journey to indicate having saving move recurrence. commercial Tempus launch. from to data requires has see we're the representatives a are who the XX decided and unnecessary holds for studies clinic positive on now and system.
In spare this for October therapies in patients just by patients with suggests potential strong our half physicians IO together treatment toxicities on the been we and potentially access ahead demand to our risk MRD Tempus are doctors meaning from first We test. earlier, the at those the The XXXX, lower cancer with marketing commercial we avoiding test started result can able accelerate able have treatment calling future, also sooner, create to money patients the switch may confidence health nation's the better negative, program. that months care that provided detect many therapy, the across and June and multiple negative through as and now promise the our
we the increased provided inform XXX from contributed success quarter-over-quarter clinical XXX quarter intervention. a the Physicians results quarter, selection therapy using increase test feedback to healthy the to as tests our have of growth delivered delivered second they year. in Our appreciate from actionability XX% in the a third this that
that region previously Now if NeXT part on region X per ultra-sensitive that blood circulating Personal detect range. remember, report been The sensitivity you DNA to down the analytic with mask to had in call we million. We about consistently. hard extra a we test, the report
a testing in the when our more moment more the ctDNA to is success for are, placing of our statistic in have monitoring QX, in to physicians to start That cancer of MRD they samples expect discrimination from have and physicians a from small market. traces take ability one approach in utilize Personal value us approach. XX% their of drive in in ordered We pleased XX% want again clinical that us cancer-free.
I the been underscores approximately recurrence testing. And earlier, high doctors in with have results jump detect our the test's demand ordered who heightened the in confidence ctDNA of this XX% to fact, physicians to patients. largely ultra-sensitive and actionability already far is negative It with QX. clinical our are to share patients The that thus see in can are means NeXT cancer more our therapy have range. positive
to our building the second and to our mentioned gain publishing on pillar. reimbursement. previously clinical We've focus evidence Moving
submission for and for Marsden cancer. work in summarized around them And continue the for into the the investigators Royal from oncology peer-reviewed journals.
We've manuscripts lung findings previously IO with some world. leading thought for top therapy fact, We to preparation breast of leaders of in VHIO are and at TRACERx of the cancer, deep many publications
be to and to our be for submission IO updates journals dossier for in publication. peer-reviewed key am published, journey, these on submitted you for publication the they collaborators each Medicare While component update providing we our reimbursement to Once are I a for data articles won't indication. now will that have pleased breast
them Spain. goal editors give While in continued during X studies Conference our our in highlighted with us XXXX achieving confidence conversations process, our the were of target ESMO of reimbursement our the XXXX.
X indications publication in collaborators the for key and publication control
continued data up First, group expanded Charlie of an podium area presented a consortium results. at the was patients to significantly Personal's update Swanton.
The TRACERx by show our cancer X detect with months presentation residual before cancer on presentation of ESMO, year's last and the compared ability to outstanding clinical lung work to in NeXT for showcased imaging the to
As studies a conducted of in reminder, lung date. MRD larger is cancer to one the this
The second collaboration Vall collaboration VHIO immunotherapy highlighted or in d'Hebron was the monitoring.
group the cancer, now breast breast used lung In Hopkins and team cancer mentioned. working platform cancer XX with working our studies lung therapy The and you gastric study monitoring, cancer therapy DARWIN and lung VHIO II. and institutions therapy VHIO, working XXX-patient has with with on than that could subtypes. called we're included of that XX other underline and For pleased potentially breast with IO prospective Marsden, in breast pan-cancer also approach have approximately as XX studies to Royal the Johns with XXX-patient IO cancer, study Vanderbilt, monitoring.
In an immunotherapy patients Curie predict we working is response patients.
I'm approximately different early-stage cancer TNBC.
In an across a working demonstrate called a TRACERx with on and with expanded the and the on on at The triple-negative PREDICT growing the with study our group update melanoma of TNBC cancer, patients. different HERX-positive across enrolled data and cancer NeXT for patients pan-cancer in an Institut HERX-positive on patients be core studying Personal we're commitment UCSD study we're study.
We're study work that Duke ongoing IO Dana-Farber TRACERx group, value to early-stage ongoing now our showed UKE with to X and therapy in and a are patients more study, the B-STRONGER-X IO an cancer indications, studies
need relationships more The trials. biopharma our strategy the of approach success. to want to NeXT Personal patients drive clinical to and to trial third select effectively in use of NeXT for our pillar accurately Personal clinical monitor leverage ultra-sensitive is trials Customers an and more
assay are to patients have our ultra-sensitive the For example, testing recurrence. much presented data negative more suggests likely with that
that that expect an then can trials. biopharma Personal these could therapeutic optimize customers patients intervention, approach excellent biopharma are out NeXT benefit promise Our to a to be less holding from the likely
ultra-sensitive get sooner imaging, time. an results for faster is ESMO Additionally, biopharma the generate our to the top than mean from appreciated.
We're world's could test, of allowing to the have at -- using monitor effectiveness discussions and potentially test over market most create value clients most ASCO. sooner NeXT biopharma we seeing drug rather continued to Indeed, drug increasingly engaged companies with recently Personal excitement and to around
We expand our through and growth projects orders revenue customers MRD continue the to XXXX. of biopharma from book accelerating to expect begin for
launch October Now a in and market the followed Tempus partner-centric we with new in of commercial relationship In where ASCO NeXT agreed in accelerate model. early we Personal program fourth final our in Tempus, chapter XXXX, began our activities. We on the the access an clinical using I'll at to June. a commercializing by move journey with to commercial pillar, August, announced the
with demand Their our as product result, efforts have approach. and salesperson in trained talking channel our interest a now XXX-plus an accelerate Our oncologists. is and been decided met strong to efforts. ultra-sensitive to we in on collectively And August,
processes they obtaining on our commercial and a provide under invoices value health reimbursement, services the focuses us. As patients lab, Tempus Personalis to and insurance market companies, samples for reminder, pays in the fair payers arrangement
Personalis, share. million million well, we're warrants Personalis part brought $XX.X August in $X.XX of a additional deal of Tempus our $XX As $XX which million investment and is invested for payments partnership for approximately the aggregate buying Tempus.
The the includes with milestone from in $XX the million exercised an shares to plus expansion, working value at equity their per $XX.X by extremely million and progress. pleased That
reimbursement. Personalis' broad and over goal next operations Our Personal clinical with usage, on is revenue to of scaled the accelerating the XX NeXT months rapidly position back
leveraging clicking engine, platform our second relationships NeXT with with While our to who deepen Win-in-MRD growth pioneering first our on along therapies. things strategy, are we've growth engine, are progress made new our also customers biopharma ImmunoID
year-over-year, had in ImmunoID XX% primarily grew product our X Customers solid business portfolio. NeXT biopharma and across platform Our we our performance use ways.
platform insights development of new that this over companies our global drug and and the research enable leverage translational to they biopharmaceutical been find with In the most biomarkers can years. regard, power efforts. XX working First, we've their top
fingerprint program. in platform patient's market therapy. the mRNA how a using create personalized neoantigen in previously tumor to vaccine to companies or cancer Second, personalized develop highlighted We've PCV their Moderna, use our our molecular therapy a of is partner, our platform individualized
important clinical of Our have collaboration its and partner, Merck, has an patients enrolled in with for Moderna Phase been trial. most revenue us Moderna and their III now for driver XXXX,
studies quarters will our finalized revenue over of their study.
We in Our from set Moderna melanoma next ramps up. accelerated enrollment Phase Moderna that anticipate they III clinical revenue from fall as back the few next the while
continue over the with to several that Moderna will years. support continue clinical We substantial relationship generate next to studies on expect and them multiple our revenue
insight our as customers. to is we and enterprise of adopt third growth growing technologies strategy The platforms approach partners relationships, Personalis In engine service these their power our solutions. our
exome leveraged a has Natera of MRD scale build work part example, in-house help as their capacities. they our product to them For to while platform
As work expect the fourth Natera to previously and our the mentioned, with by we quarter. this transitioned wind work they've end of in-house, down
support accelerating, is and we other clinical capacity Natera efforts. are While previously diagnostic business our these the earmarked for biopharma to shifting strategic
whole program [Technical the program feedback renewed September, VA Veteran veterans.
We've sequencing second quarter capabilities in grateful continue to than looking order the continue a XXXX.
It's for for fulfill the helping now. NeXT Personalis, national The clients, in also team at expect and our another years and we we how VA XX contract power the at us quarter, We're relationship MRD to turn guidance utilizes more million collaborators as to We in all it excellent a patients' lives Personal year. the the company enterprise approach. I'll sequencing special is with purchase that helped Million the fight now $X.X other of partners them.
A discussions Program, research and And about financial companies power have to new redefine win is sensitive more a early doing this for helping and market genome results. against that to another our their Aaron us a cancer.
With genes over building impacting this with to review with to amount We work, VA. Difficulty] our lifestyle received work that, and been for to I'm our the
